Aging
Navigate
Research Paper|Volume 12, Issue 1|pp 866—883

Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma

Hua Xu1,2, Wen-Hao Xu1,2, Fei Ren2,3, Jun Wang1,2, Hong-Kai Wang1,2, Da-Long Cao1,2, Guo-Hai Shi1,2, Yuan-Yuan Qu1,2, Hai-Liang Zhang1,2, Ding-Wei Ye1,2
  • 1Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
  • 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • 3Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
* Equal contribution
Received: September 10, 2019Accepted: December 24, 2019Published: January 8, 2020

Copyright: © 2020 Xu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Epithelial-to-mesenchymal transition (EMT) is important in tumor invasiveness and metastasis. We aimed to determine prognostic value of six key EMT markers (CDH1, CDH2, SNAI1, SNAI2, VIM, TWIST1) in clear cell renal cell carcinoma (ccRCC). A total of 533 ccRCC patients with RNASeq data from The Cancer Genome Atlas (TCGA) cohort were included for analysis. Gene expression of these EMT markers was compared between tumor and normal tissues based on Oncomine database and TCGA cohort. Their correlations with progression-free survival (PFS) and overall survival (OS) were also examined in both TCGA cohort and FUSCC (Fudan University Shanghai Cancer Center) cohort. Cox proportional hazards regression model and Kaplan-Meier plot were used to assess the relative factors. Functional enrichment analyses were utilized to describe biologic function annotations and significantly involved hallmarks pathways of each gene. We found that Epithelial marker, CDH1 expression was lower, while mesenchymal markers (CDH2, SNAI1, VIM, TWIST1) expression was higher in ccRCC primary tumors. In the TCGA cohort, we found that patients with higher expression of VIM, TWIST1 or lower expression of CDH1 had worse prognosis. Further, in the FUSCC cohort, we confirmed the predictive ability of mesenchymal markers and epithelial marker expression in PFS and OS of ccRCC patients. After generating Cox regression models, EMT markers (CDH1, SNAI1, VIM, and TWIST1) were independent prognostic factors of both PFS and OS in ccRCC patients. Our preliminary EMT prediction model can facilitate further screening of EMT biomarkers and cast a better understanding of EMT gene function in ccRCC.